Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, adding it had the required two-months of safety data and would apply for emergency US authorisation within days.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.
Equity markets strengthened slightly on the news. Europe’s STOXX 600 and US S&P 500 e-mini futures both hit session highs.
However, the moves were small compared to the jump after Pfizer’s previous announcement. The reaction in European government bonds and in currencies was muted.
Pfizer shares rose 3% to $37.19 and US-listed shares of partner BioNTech SE were up 8% at $94.80 in premarket trading.
Eleanor Riley, professor of immunology and infectious disease, at the University of Edinburgh says, “We can be fairly confident now that the RNA (vaccine approach) is looking good…That’s also good for the Imperial College vaccine, which is an RNA vaccine.”
“The 94% protection for older people is key – this is the evidence we needed to ensure that the most vulnerable people are protected,” Andrew Hill, senior visiting research fellow, department of pharmacology, University of Liverpool.
The post Pfizer ends COVID-19 trial with 95% efficacy appeared first on SABC News – Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader..